Vantia Therapeutics announced recently that it had revealed the structure of oral small-molecule drug candidate VA111913, a potential new treatment for dysmenorrhoea, for the first time.
29 March, 2010
Cellzome announces second major strategic drug discovery alliance with GlaxoSmithKline in inflammatory disease.
10 March, 2010